On July 31, Illumina fell 5.52% in regular trading, trading at $193.07 USD/share, with turnover of $206 million. The stock had initially surged over 5% in early trading before reversing sharply into negative territory, exhibiting a classic spike-and-retreat pattern.
On the news front, Illumina reported Q2 adjusted EPS of $1.31, beating the consensus estimate of $1.23, while revenue of $1.159 billion also topped the $1.130 billion estimate. Full-year revenue guidance was maintained at $4.52 billion to $4.62 billion, above market expectations. Additionally, RBC raised its price target from $170 to $230, maintaining an Outperform rating. Despite uniformly positive fundamental data and an analyst upgrade, the stock experienced significant profit-taking after the initial gap higher, suggesting investors had largely priced in the strong results ahead of the release.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments